

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 90763

Title: Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05395205

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Doctor, Postdoc

Reviewer's Country/Territory: China

Author's Country/Territory: Japan

Manuscript submission date: 2024-01-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-01-10 13:36

Reviewer performed review: 2024-01-10 13:45

Review time: 1 Hour

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this study the authors investigate the long-term efficacy and safety of TOF treatment for UC. Some suggestions are listed as below: Why week 8 and week 48 were selected as outcomes in this study? Safey data should be provided. Why these patients with UC were treated with TOF, rather than other treatments. Potential selection bias should not be ignored. Had this study been registered before?